Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

CTX110 Allogeneic CRISPR-Cas9-Engineered CAR T Cells in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 1 Dose Escalation Carbon Study

Blood (2022) 140 (Supplement 1): 10303–10306.

https://doi.org/10.1182/blood-2022-166432

Published: 2022

Journal Articles

Reduction in Transplantation Activity without Impairment in Outcomes in the Covid-19 Era- Data from the Sarah Cannon Blood Cancer Network (SCBCN)

Minoo Battiwalla, MD, Carlos Bachier, MD, Vikas Bhushan, MD, Michael J. Eckrich, MD MPH, Alireza Eghtedar, MD, Haydar Frangoul, MD, Suman Kambhampati, MD, Shahbaz Malik, MD, Peter A. McSweeney, MD, Jeremy Pantin, MBBS, Aravind Ramakrishnan, MD, Hana Safah, MD, Paul J Shaughnessy, MD, Betsy Blunk, BSN, RN, BMTCN, Tonya Cox, BSN, RN, Rocky Billups, MS, Charles F. Lemaistre, MD

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-139121

Published: 2020

Journal Articles

The CLL-1100 Project: Towards Complete Genomic Characterization and Improved Prognostics for CLL

Blood (2020) 136 (Supplement 1): 3–4.

https://doi.org/10.1182/blood-2020-140987

Published: 2020

Journal Articles

Incidence of Germline ATM Variants in a Consecutive Clinical Cohort of CLL Patients

Benjamin L. Lampson, MD PhD, Svitlana Tyekucheva, PhD, Conner J. Shaughnessy, Annette S. Kim, MD PhD, Jennifer R. Brown, MD PhD

Blood (2019) 134 (Supplement_1): 1731.

https://doi.org/10.1182/blood-2019-127180

Published: 2019

Journal Articles

Open-Label Study to Determine the Feasibility of Ixazomib As Maintenance after Allogeneic Stem Cell Transplant for Multiple Myeloma

Carlos R Bachier, MD, Paul J Shaughnessy, MD, Jeffrey V Matous, MD, Jesus G. Berdeja, MD

Blood (2017) 130 (Supplement 1): 5537.

https://doi.org/10.1182/blood.V130.Suppl_1.5537.5537

Published: 2017

Journal Articles

A Prospective Randomized Double Blind Phase 3 Clinical Trial of Anti- T Lymphocyte Globulin (ATLG) to Assess Impact on Chronic Graft-Versus-Host Disease (cGVHD) Free Survival in Patients Undergoing HLA Matched Unrelated Myeloablative Hematopoietic Cell Transplantation (HCT)

Blood (2016) 128 (22): 505.

https://doi.org/10.1182/blood.V128.22.505.505

Published: 2016

Journal Articles

Outcomes of Autologous Transplants for Patients with Multiple Myeloma and Concurrent Multiple Plasmacytomas

Seema Naik, MD, Paul J. Shaughnessy, MD, Behyar Zoghi, MDPhD, Jose C Cruz, MD, Carlos Bachier, MD

Blood (2015) 126 (23): 1973.

https://doi.org/10.1182/blood.V126.23.1973.1973

Published: 2015

Journal Articles

The VIP (Very Immunocompromised Patient) Protocol: Improved Access To Care and Time To Antibiotics

Paul J. Shaughnessy, MD, Ann Kelley, RN, Roberta Tremper, RN, Jonathan Tinker, Carlos Bachier, MD, Joseph Holahan, MD, Roger M. Lyons, MD, Charles F. LeMaistre, MD

Blood (2013) 122 (21): 2978.

https://doi.org/10.1182/blood.V122.21.2978.2978

Published: 2013

Journal Articles

Final Report of Safety and Efficacy From a Novel Conditioning Regimen, Individualized Once-Daily Intravenous Busulfan with Bortezomib, in Relapsed Multiple Myeloma Patients Undergoing a Second Autologous Hematopoietic Stem Cell Transplantation.

Blood (2012) 120 (21): 3080.

https://doi.org/10.1182/blood.V120.21.3080.3080

Published: 2012

Journal Articles

Pharmacokinetics and Safety of a Novel Conditioning Regimen, Individualized Once-Daily Intravenous Busulfan with Bortezomib, in Relapsed Multiple Myeloma Patients Undergoing a Second Autologous Hematopoietic Stem Cell Transplantation

Cesar O. Freytes, MD, Juan J. Toro, MD, MSci, Rosa F. Yeh, PharmD, Edward A. Stadtmauer, MD, Voravit Ratanatharathorn, MD, Gorgun Akpek, MD, MHS, Entezam Sahovic, MD, Guido J. Tricot, MD, PhD, Paul J. Shaughnessy, MD, Darrell J. White, MD, Tulio E. Rodriguez, MD, Scott R. Solomon, MD, Louie H. Yu, BS, Shiva Patil, PhD, Yiping Sun, PhD, Elizabeth Armstrong, MS, Agnes Elekes, MD, Kazunobu Kato, MD, PhD, Donna E. Reece, MD, FRCPC

Blood (2011) 118 (21): 4509.

https://doi.org/10.1182/blood.V118.21.4509.4509

Published: 2011

Journal Articles

Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease

Paul J. Martin, Barry E. Storer, Scott D. Rowley, Mary E. D. Flowers, Stephanie J. Lee, Paul A. Carpenter, John R. Wingard, Paul J. Shaughnessy, Marcel P. DeVetten, Madan Jagasia, Joseph W. Fay, Koen van Besien, Vikas Gupta, Carrie Kitko, Laura J. Johnston, Richard T. Maziarz, Mukta Arora, Pamala A. Jacobson, Daniel Weisdorf

Blood (2009) 113 (21): 5074–5082.

https://doi.org/10.1182/blood-2009-02-202937

Published: 2009

Includes: Supplemental data

Journal Articles

Once Daily Busulfan Cyclophosphamide Is Well Tolerated and Effective Prior to Allogeneic Hematopoietic Stem Cell Transplantation.

Julia A. LeMaistre, Carlos Bachier, MD, Brad Smith, PhD, C.F. LeMaistre, MD, Paul J. Shaughnessy, MD

Blood (2007) 110 (11): 1996.

https://doi.org/10.1182/blood.V110.11.1996.1996

Published: 2007

Journal Articles

Once Daily Busulfan and Fludarabine Is Well Tolerated and Effective in Older Heavily Treated Patients Prior to Unrelated Donor Allogeneic Peripheral Blood Stem Cell Transplant.

Grant W. Potter, Carlos Bachier, MD, Brad Smith, PhD, Maureen Hougham, C.F. LeMaistre, MD, Paul J. Shaughnessy, MD

Blood (2007) 110 (11): 4950.

https://doi.org/10.1182/blood.V110.11.4950.4950

Published: 2007

Journal Articles

Pharmacogenomics (PGx) Research in the APEX Randomized Multicenter International Phase 3 Trial Comparing Bortezomib and High-Dose Dexamethasone (Dex).

G. Mulligan, C. Mitsiades, B. Bryant, F. Zhan, W. Cheng, S. Eschrich, B. Burrington, P. Richardson, W. Trepicchio, J. Shaughnessy, L. Bergsagel, A. Damokosh, A. Boral, D. Esseltine, D. Schenkein, K. Anderson

Blood (2005) 106 (11): 3491.

https://doi.org/10.1182/blood.V106.11.3491.3491

Published: 2005

Journal Articles

Killer Immunoglobulin-Like Receptor Ligand (KIR-Lig) Mismatched Natural Killer (NK) Cell Transfusions for Multiple Myeloma (MM).

J. Shi, MD, PhD, S. Szmania, BS, N. Rosen, BS, A. Moreno, BS, R. Walker, MD, B. DuPont, MD, K. Hsu, MD, L.A. Baxter-Lowe, PhD, J. Shaughnessy, PhD, B. Barlogie, MD, PhD, M. Cottler-Fox, MD, G. Tricot, MD, PhD, F. van Rhee, MD, PhD

Blood (2005) 106 (11): 3472.

https://doi.org/10.1182/blood.V106.11.3472.3472

Published: 2005

Journal Articles

Intravenous Busulfan Dosed Once Daily or Four Times Daily as Part of the Standard BuCy Preparative Regimen for Allogeneic Stem Cell Transplantation.

Paul J. Shaughnessy, MD, Carlos Bachier, MD, Lorraine Alexander, C. F. LeMaistre, MD

Blood (2005) 106 (11): 5327.

https://doi.org/10.1182/blood.V106.11.5327.5327

Published: 2005

Journal Articles

Comparison between G-CSF and GM-CSF for Mobilization of Dendritic Cells, CD34+ Cells, and CD3+ Cells in Normal Donors.

Paul J. Shaughnessy, MD, Carlos Bachier, MD, Al Nanez, BS, Cagla Akay, MD, C. F. LeMaistre, MD, Yair Gazitt, PhD

Blood (2004) 104 (11): 2870.

https://doi.org/10.1182/blood.V104.11.2870.2870

Published: 2004

Journal Articles

A Multi-Institutional Study of Extracorporeal Photoimmune Therapy with UVADEX® for the Prevention of Acute GVHD in Patients Undergoing Standard Myeloablative Conditioning and Allogeneic Hematopoietic Stem Cell Transplantation.

Paul J. Shaughnessy, MD, Brian J. Bolwell, MD, Sunil Abhyankar, MD, Koen van Besien, MD, Martin Mistrik, MD PhD, Andrew Grigg, MBBS, Anthony Dodds, MBBS, H. Miles Prince, MBBS, Alexandra Machado, MD, Ulrich Thienel, MD, PhD, Jim Wang, Francine Foss, MD, Jane Apperley, MBChB

Blood (2004) 104 (11): 1230.

https://doi.org/10.1182/blood.V104.11.1230.1230

Published: 2004

NARROW

CTX110 Allogeneic CRISPR-Cas9-Engineered CAR T Cells in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 1 Dose Escalation Carbon Study

Reduction in Transplantation Activity without Impairment in Outcomes in the Covid-19 Era- Data from the Sarah Cannon Blood Cancer Network (SCBCN)

The CLL-1100 Project: Towards Complete Genomic Characterization and Improved Prognostics for CLL

Incidence of Germline ATM Variants in a Consecutive Clinical Cohort of CLL Patients

Open-Label Study to Determine the Feasibility of Ixazomib As Maintenance after Allogeneic Stem Cell Transplant for Multiple Myeloma

A Prospective Randomized Double Blind Phase 3 Clinical Trial of Anti- T Lymphocyte Globulin (ATLG) to Assess Impact on Chronic Graft-Versus-Host Disease (cGVHD) Free Survival in Patients Undergoing HLA Matched Unrelated Myeloablative Hematopoietic Cell Transplantation (HCT)

Outcomes of Autologous Transplants for Patients with Multiple Myeloma and Concurrent Multiple Plasmacytomas

The VIP (Very Immunocompromised Patient) Protocol: Improved Access To Care and Time To Antibiotics

Final Report of Safety and Efficacy From a Novel Conditioning Regimen, Individualized Once-Daily Intravenous Busulfan with Bortezomib, in Relapsed Multiple Myeloma Patients Undergoing a Second Autologous Hematopoietic Stem Cell Transplantation.

Pharmacokinetics and Safety of a Novel Conditioning Regimen, Individualized Once-Daily Intravenous Busulfan with Bortezomib, in Relapsed Multiple Myeloma Patients Undergoing a Second Autologous Hematopoietic Stem Cell Transplantation

Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease

Once Daily Busulfan Cyclophosphamide Is Well Tolerated and Effective Prior to Allogeneic Hematopoietic Stem Cell Transplantation.

Once Daily Busulfan and Fludarabine Is Well Tolerated and Effective in Older Heavily Treated Patients Prior to Unrelated Donor Allogeneic Peripheral Blood Stem Cell Transplant.

Pharmacogenomics (PGx) Research in the APEX Randomized Multicenter International Phase 3 Trial Comparing Bortezomib and High-Dose Dexamethasone (Dex).

Killer Immunoglobulin-Like Receptor Ligand (KIR-Lig) Mismatched Natural Killer (NK) Cell Transfusions for Multiple Myeloma (MM).

Intravenous Busulfan Dosed Once Daily or Four Times Daily as Part of the Standard BuCy Preparative Regimen for Allogeneic Stem Cell Transplantation.

Comparison between G-CSF and GM-CSF for Mobilization of Dendritic Cells, CD34+ Cells, and CD3+ Cells in Normal Donors.

A Multi-Institutional Study of Extracorporeal Photoimmune Therapy with UVADEX® for the Prevention of Acute GVHD in Patients Undergoing Standard Myeloablative Conditioning and Allogeneic Hematopoietic Stem Cell Transplantation.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only